Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 20/20 | 0.54 |
| ▸ | CDK9 | P50750 | 20/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178407 | 0.85 | CCNT1 (0.50) | CCNT1CDK9CDK1CDK4CDK2 | |
| SCHEMBL27553178 | 0.83 | MEN1 (0.45) | CCNT1CDK9CDK1CDK4CDK2 | |
| SCHEMBL6179323 | 0.82 | CCNT1 (0.67) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL6177059 | 0.79 | CCNT1 (0.49) | CCNT1CDK9 | |
| Cyclohexane SCHEMBL6181993 | 0.77 | PPARG (0.52) | CCNT1CDK9 | |
| SCHEMBL6176762 | 0.75 | MEN1 (0.51) | CCNT1CDK9 | |
| SCHEMBL6180652 | 0.75 | PPARG (0.52) | CCNT1CDK9 | |
| SCHEMBL6177022 | 0.73 | MEN1 (0.51) | CCNT1CDK9 | |
| SCHEMBL6179380 | 0.72 | PPARG (0.47) | CCNT1CDK9 | |
| SCHEMBL6178731 | 0.72 | PPARG (0.49) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140830-B1 | ARYLPIPERIDINE AND ARYL-1,2,5,6-TETRAHYDROPYRIDINE AMIDE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | WYETH CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6503928-B2 | Central nervous system disorders; psychological disorders | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-6326381-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | disclosed |
| US-6239126-B1 | ANTAGONISTS OF THE 5HT1A RECEPTOR SUBTYPE. | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | ADRA1D, ADH1C, HTR1D | CCNT1 2029/4885CDK9 881/4885CDK1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.